Central Library

1.

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations

Bodó, I;Amine, I;Boban, A;Bumbea, H;Kulagin, A;Lukina, E;Piekarska, A;Zupan, IP;Sokol, J;Windyga, J;Cermak, J

Q1

ADVANCES IN THERAPY

2023.

DOI:10.1007/s12325-023-02510-4 (Copy DOI)

Semmelweis University authors: Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Belgyógyászati és Hematológiai Klinika,

2.

von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

Pagliari, M.T.; Budde, U.; Baronciani, L.; Eshghi, P.; Ahmadinejad, M.; Badiee, Z.; Baghaipour, M.-R.; Hidalgo, O.B.; Biguzzi, E.; Bodó, I.; Castaman, G.; Goudemand, J.; Karimi, M.; Keikhaei, B.; Lassila, R.; Leebeek, F.W.G.; Lopez, Fernandez M.F.; Marino, R.; Oldenburg, J.; Peake, I.; Santoro, C.; Schneppenheim, R.; Tiede, A.; Toogeh, G.; Tosetto, A.; Trossaert, M.; Yadegari, H.; Zetterberg, E.M.K.; Mannucci, P.M.; Federici, A.B.; Eikenboom, J.; Peyvandi, F.;

D1

JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1538-7933 1538-7836

2023.

DOI:10.1016/j.jtha.2023.01.001 (Copy DOI)

Semmelweis University authors: Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Belgyógyászati és Hematológiai Klinika,

3.

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen

Simon, B;Ceglédi, A;Dolgos, J;Farkas, P;Gaddh, M;Hankó, L;Horváth, R;Kaposi, A;Magyar, L;Masszi, T;Szederjesi, A;Wohner, N;Bodó, I

D1

BLOOD

2022.

DOI:10.1182/blood.2022016873 (Copy DOI)

Semmelweis University authors: Simon , Barbara, Lehoczki, Andrea Marianna, Farkas, Péter, Kaposi, Ambrus, Masszi, Tamás, Szederjesi, Attila, Wohner, Nikolett, Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Belgyógyászati és Hematológiai Klinika,

4.

Acquired hemophilia A as a disease of the elderly: A comprehensive review of epidemiology, pathogenesis, and novel therapy

Lehoczki, A;Fekete, M;Mikala, G;Bodó, I

D1

GEROSCIENCE

2024.

DOI:10.1007/s11357-024-01317-7 (Copy DOI)

Semmelweis University authors: Lehoczki, Andrea Marianna, Fekete, Mónika, Mikala, Gábor, Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Institute for Preventive Medicine and Public Health, Belgyógyászati és Hematológiai Klinika, School of PhD Studies,

5.

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

Pulanic, D;Batorova, A;Bodo, I;Cervinek, L;Ionita, I;Lissitchkov, T;Melikyan, A;Podolak-Dawidziak, M

Q1

ANNALS OF HEMATOLOGY

2023.

DOI:10.1007/s00277-023-05114-8 (Copy DOI)

Semmelweis University authors: Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Belgyógyászati és Hematológiai Klinika, III. Department of Internal Medicine,

6.

Matrilineal Composition of the Reconstructed Stock of the Szekler Horse Breed

Gáspárdy, A;Wagenhoffer, Z;Fürlinger, D;Halmágyi, M;Bodó, I;Lancioni, H;Maróti-Agóts, A

Q1

AGRICULTURE-BASEL

2023.

DOI:10.3390/agriculture13020456 (Copy DOI)

Semmelweis University authors: Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Belgyógyászati és Hematológiai Klinika,

7.

Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

Baronciani, L;Peake, I;Schneppenheim, R;Goodeve, A;Ahmadinejad, M;Badiee, Z;Baghaipour, MR;Benitez, O;Bodó, I;Budde, U;Cairo, A;Castaman, G;Eshghi, P;Goudemand, J;Hassenpflug, W;Hoorfar, H;Karimi, M;Keikhaei, B;Lassila, R;Leebeek, FWG;Fernandez, MFL;Mannucci, PM;Marino, R;Niksic, N;Oyen, F;Santoro, C;Tiede, A;Toogeh, G;Tosetto, A;Trossaert, M;Zetterberg, EMK;Eikenboom, J;Federici, AB;Peyvandi, F

D1

BLOOD ADVANCES

2021.

DOI:10.1182/bloodadvances.2020003397 (Copy DOI)

Semmelweis University authors: Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Belgyógyászati és Hematológiai Klinika,

8.

Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study

Tosetto, A;Badiee, Z;Baghaipour, MR;Baronciani, L;Battle, J;Berntorp, E;Bodó, I;Budde, U;Castaman, G;Eikenboom, JCJ;Eshghi, P;Ettorre, C;Goodeve, A;Goudemand, J;Richard, C;Hay, M;Hoorfar, H;Karimi, M;Keikhaei, B;Lassila, R;Leebeek, FWG;Fernandez, MFL;Mannucci, PM;Mazzucconi, MG;Morfini, M;Oldenburg, J;Peake, I;Lòpez, RP;Peyvandi, F;Schneppenheim, R;Tiede, A;Toogeh, G;Trossaert, M;Zekavat, O;Zetterberg, EMK;Federici, AB

D1

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

2020.

DOI:10.1111/jth.14886 (Copy DOI)

Semmelweis University authors: Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Belgyógyászati és Hematológiai Klinika,

9.

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

Pagliari, MT;Rosendaal, FR;Ahmadinejad, M;Badiee, Z;Baghaipour, MR;Baronciani, L;Hidalgo, OB;Bodó, I;Budde, U;Castaman, G;Eshghi, P;Goudemand, J;Karimi, M;Keikhaei, B;Lassila, R;Leebeek, FWG;Fernandez, MFL;Mannucci, PM;Marino, R;Oldenburg, J;Peake, I;Santoro, C;Schneppenheim, R;Tiede, A;Toogeh, G;Tosetto, A;Trossaert, M;Yadegari, H;Zetterberg, EMK;Peyvandi, F;Federici, AB;Eikenboom, J

D1

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

2022.

DOI:10.1111/jth.15658 (Copy DOI)

Semmelweis University authors: Bodó, Imre,

Semmelweis University departments: Semmelweis University, Faculty of Medicine, Belgyógyászati és Hematológiai Klinika,

10.

Rituximab leads to early elimination of circulating CD20⁺ T and B lymphocytes in patients with iTTP despite ongoing TPEx

Carden, MA;Gaddh, M;Hoskote, A;Brown, M;Merrill, V;Stowell, SR;Chandrakasan, S;Antun, A;Kudchadkar, R;Kotanchiyev, S;Jaye, DL;Bodó, I

D1

BLOOD ADVANCES

2020.